Tuesday May 14
|Chairman: Dr Robert Scoffin|
|12.30||Lunch and registration|
|13.00||Upcoming features and future horizons
Dr Mark Mackey, Chief Scientific Officer, Cresset
|13.20||Ligand-based virtual screening: How can we do better?
Rajeshri Karki, Novartis
|13.40||Using field based chemistry methods to understand sequence-specific protein-DNA interactions Daniel Barr, Utica College|
|14.00||The trend to outsource computational chemistry
Dr Martin Slater, Director of Consulting, Cresset
|14.20||Afternoon break and networking|
|Chairman: Dr Mark Mackey|
|14.50||New drugs from old compounds
Dr Robert Scoffin, Chief Executive Officer, Cresset
|15.10||Drug hunts with Spark: case studies from the literature and current campaigns to develop immunokinase inhibitors
Dr Alfred M Ajami, DCAM Pharma Inc.
|15.30||Performance of XedEx and other conformational search algorithms on flexible scaffolds
Dr Patrick McCarren, The Broad Institute
|15.50||Identification of a novel inhibitor of HIV-1 entry using scaffold-hopping and bioisosteric replacement
Dr Simon Cocklin, Drexel University
|16.10||Chairman’s closing remarks|
The program is open to change.